Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Company News Summary

Telix Pharmaceuticals Announces Regarding $12.1m R&D Tax Refund and Overseas Finding Increased to $139m

28 Sep 2021  |  08:33:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: $12.1M R&D Tax Refund, Overseas Finding Increased to $139M

Telix Pharmaceuticals announced that it has received a $12.1m R&D tax refund in relation to eligible R&D activities undertaken by the Company in the year ended 31 December 2020. The Company is to advise that its application for an expanded overseas finding, to enable partial recovery of essential overseas R&D expenditure has been accepted by the Department of Industry, Science, Energy and Resources. It received an advance finding in relation to its proposed pre-clinical, clinical, manufacturing and regulatory-related activities. The enabled the Company to claim an R&D tax rebate on eligible R&D investment, up to a gross amount of $55.2m over five years.

Please click here for full details

See more ASX300 News Announcements